CAC Score of Zero but High Lp(a): Are You Still at Risk?

High Lp(a) and a zero coronary calcium score often create confusion because the results seem to tell opposite stories. One suggests increased cardiovascular risk, while the other is among the most reassuring findings available in primary prevention.

Both results can be accurate at the same time. The apparent conflict comes from asking one test to answer the question addressed by the other. Lp(a) describes inherited atherogenic risk over time. CAC identifies calcified coronary plaque that has already developed. Understanding that distinction makes the combination much easier to interpret.

CAC and Lp(a) Measure Different Parts of Cardiovascular Risk

Lipoprotein(a) is an apoB-containing lipoprotein particle whose concentration is determined primarily by genetics. Levels are generally stable throughout adult life, which is why major cardiovascular guidelines now recommend measuring Lp(a) at least once in adulthood.

Higher Lp(a) concentrations are associated with greater lifetime risk of atherosclerotic cardiovascular disease and calcific aortic valve disease. The laboratory result does not establish that coronary plaque is already present; it identifies a biologic risk factor that increases the likelihood of disease developing over time.

A coronary artery calcium scan answers a different question. The noncontrast CT scan identifies calcium within coronary atherosclerotic plaque and provides a quantitative measure of calcified plaque burden. It does not measure circulating atherogenic particles, genetic susceptibility, or noncalcified plaque.

This is why a genetically high Lp(a) can coexist with a CAC score of zero. One result describes an inherited tendency toward future atherosclerotic disease, while the other shows that detectable calcified coronary plaque has not yet developed.

For more on the biology and clinical significance of Lp(a), see Lp(a): The Inherited Heart Risk Most People Have Never Measured.

A Calcium Score of Zero Is Genuinely Good News

Advanced preventive cardiology has appropriately emphasized the limitations of coronary calcium scanning, particularly its inability to visualize noncalcified plaque. That limitation should not obscure the substantial prognostic value of a zero score.

Across large prospective cohorts, people with no detectable coronary calcium have substantially lower cardiovascular event rates than people with established calcified plaque. CAC = 0 is therefore one of the strongest negative risk markers available in primary prevention.

The 2026 ACC/AHA dyslipidemia guideline continues to incorporate this information into treatment decisions. In selected adults with borderline or intermediate risk, a zero calcium score may support deferring lipid-lowering medication for a period of time when major higher-risk conditions are absent.

This does not imply an absence of cardiovascular risk. It indicates that the current burden of detectable calcified coronary atherosclerosis is low enough to meaningfully lower near-term risk estimates.

HormoneSynergy® discusses the limitations and value of a zero calcium score in greater detail in Calcium Score of Zero: Why It Doesn't Mean Zero Risk.

Why Elevated Lp(a) Still Matters

A favorable calcium scan does not change the inherited Lp(a) concentration. The 2026 ACC/AHA dyslipidemia guideline considers Lp(a) levels of approximately 125 nmol/L or 50 mg/dL and above elevated, with cardiovascular risk increasing progressively at higher concentrations.

Population data suggest that an Lp(a) around 125 nmol/L is associated with roughly 40% greater long-term ASCVD risk compared with a population median, while concentrations in the range of 200 to 250 nmol/L are associated with approximately twice the long-term risk.

These figures describe population-level associations rather than an individual prediction. The clinical significance of Lp(a) depends heavily on the surrounding risk profile. A person with high Lp(a), low apoB, normal blood pressure, favorable metabolic health, no smoking exposure, and no detectable plaque has a different cardiovascular phenotype from someone with the same Lp(a) accompanied by diabetes, hypertension, elevated apoB, smoking, or established coronary disease.

Elevated Lp(a) is therefore best used as a reason to manage the rest of cardiovascular risk more carefully rather than as proof that coronary disease is already present.

What Happens When Lp(a) Is High but CAC Is Zero?

This question was examined directly in an analysis of more than 6,500 asymptomatic adults from the Multi-Ethnic Study of Atherosclerosis and the Dallas Heart Study. Participants had both Lp(a) and coronary calcium measured and were followed for cardiovascular outcomes.

Over a median follow-up exceeding 13 years in MESA, both elevated Lp(a) and higher CAC were independently associated with cardiovascular risk across the population. The interaction between the two measures, however, provided particularly useful clinical information.

Participants with elevated Lp(a) and CAC scores of 100 or greater had the highest cardiovascular risk. In contrast, participants with elevated Lp(a) but CAC = 0 had event rates statistically similar to those with lower Lp(a) and CAC = 0. The Dallas Heart Study showed a comparable pattern.

These findings support taking a zero calcium score seriously even when Lp(a) is elevated. A patient with Lp(a) of 200 nmol/L and CAC = 0 does not have the same short- or intermediate-term risk profile as a patient with the same Lp(a) and extensive calcified coronary plaque.

Near-Term and Lifetime Risk Are Different Clinical Questions

The apparent conflict between CAC and Lp(a) becomes easier to understand when risk is considered over different time horizons.

CAC = 0 is especially informative about current plaque burden and near-term coronary risk. Elevated Lp(a) remains relevant over a much longer period because it represents a persistent inherited exposure that can contribute to atherosclerosis over decades.

Age therefore changes interpretation. A 45-year-old with very high Lp(a) and no coronary calcium may still have many years for plaque to develop, while a 75-year-old with the same Lp(a) and CAC = 0 has demonstrated several additional decades without developing detectable calcified coronary atherosclerosis.

Preventive cardiology works best when those differences are incorporated rather than compressed into a single rule based on one laboratory value.

The Noncalcified Plaque Question

Coronary atherosclerosis does not begin as calcium. Earlier plaque is often noncalcified and may later become mixed or more heavily calcified as the disease evolves. A coronary calcium scan is excellent at detecting calcium, but it is not designed to characterize the coronary vessel wall or quantify noncalcified plaque.

This limitation has become particularly relevant in Lp(a) research. A 2026 coronary CT angiography study evaluating more than 3,600 individual coronary plaques found that Lp(a) concentrations of 150 nmol/L or greater were independently associated with greater noncalcified plaque volume and a higher prevalence of high-risk plaque features. Calcified plaque volume did not show the same association in that analysis.

A separate 2026 meta-analysis involving nearly 20,000 participants also associated elevated Lp(a) with greater coronary plaque burden, plaque progression, and low-attenuation plaque.

These findings provide a plausible explanation for why a person with high Lp(a) may have a zero calcium score while still carrying some noncalcified coronary plaque. They do not imply that everyone with elevated Lp(a) has hidden coronary disease or that every zero calcium score should be followed by more imaging.

When Does CCTA Make Sense?

Coronary CT angiography uses contrast-enhanced CT imaging to visualize the coronary arteries directly. Unlike a calcium scan, CCTA can identify both calcified and noncalcified plaque, evaluate stenosis, and provide a more complete picture of coronary atherosclerosis.

The additional information can be useful when a zero calcium score does not fully resolve the clinical question. At HormoneSynergy®, we may consider a lower threshold for advanced coronary imaging when elevated Lp(a) is accompanied by features such as a strong family history of premature coronary disease, persistently high apoB or LDL-C, diabetes or significant insulin resistance, smoking, chronic inflammatory disease, multiple cardiovascular risk enhancers, unexpectedly high risk for age, concerning symptoms, or substantial discordance between biomarkers and conventional risk estimates.

The value of CCTA depends on whether finding noncalcified plaque would meaningfully alter prevention or treatment. Additional imaging is most useful when it changes the clinical decision rather than simply adding another layer of information.

For a detailed comparison, see Coronary Calcium Score vs CCTA with Cleerly® Plaque Analysis.

Where Cleerly® Fits

Cleerly® is an AI-assisted quantitative analysis applied to appropriate CCTA images rather than a separate imaging study. Standard coronary CT angiography provides the underlying coronary images, while Cleerly® software can further quantify plaque burden and characterize calcified and noncalcified components.

This can be useful when the clinical question extends beyond whether coronary plaque exists to how much plaque is present and how that burden is distributed among different plaque types.

HormoneSynergy® offers Cleerly® CCTA plaque analysis in Portland and Lake Oswego, Oregon for appropriately selected patients. It is not our routine next step after every elevated Lp(a), but it can provide valuable information when advanced plaque characterization is likely to influence management.

Does CAC = 0 Mean Cholesterol-Lowering Treatment Is Unnecessary?

A zero calcium score can reasonably alter the treatment discussion in selected patients, but it does not create a universal answer.

The 2026 ACC/AHA guideline allows CAC = 0 to support deferring lipid-lowering therapy in some borderline- or intermediate-risk adults when major higher-risk conditions are absent. Important exceptions include severe hypercholesterolemia, familial hypercholesterolemia, diabetes in adults over 40, current smoking, and a strong family history of premature ASCVD.

Elevated Lp(a) adds another layer to that decision. The same guideline recommends earlier and more intensive management of modifiable cardiovascular risk in people with high Lp(a), and the marker can favor initiation or intensification of lipid-lowering therapy depending on the overall risk profile.

In practice, CAC and Lp(a) are interpreted together with age, apoB, LDL-C, metabolic health, blood pressure, family history, smoking, plaque burden, symptoms, and patient preference. A zero score may substantially lower immediate concern without making inherited risk irrelevant.

Statins Do Not Lower Lp(a), but They Can Still Reduce Risk

Statins primarily reduce LDL-C and apoB-containing lipoprotein exposure. They do not meaningfully lower Lp(a), and modest increases in Lp(a) have been reported after statin initiation in some patients.

That does not negate the cardiovascular benefit of statin therapy when it is otherwise indicated. Lowering the remainder of the atherogenic particle burden remains valuable even when the inherited Lp(a) concentration itself is unchanged.

This is especially relevant in patients with high Lp(a), because limiting exposure to other apoB-containing particles reduces an important component of modifiable risk while Lp(a)-specific therapies continue to evolve.

For more on how statin therapy can change coronary plaque composition and calcium density, see Can Statins Raise Your Calcium Score While Reducing Heart Risk?.

Why ApoB Becomes Particularly Useful

Lp(a) itself contains apoB, but so do LDL, IDL, VLDL remnants, and other atherogenic lipoproteins. ApoB therefore provides a broader measure of the number of atherogenic particles circulating in the bloodstream.

In a patient with elevated Lp(a), apoB helps determine whether inherited risk is being compounded by a high burden of other atherogenic particles. A normal LDL-C does not always imply an optimal apoB, particularly when triglycerides, insulin resistance, or other metabolic factors are present.

At HormoneSynergy®, preventive cardiovascular assessment may include Lp(a), apoB, LDL-C, non-HDL cholesterol, triglycerides, blood pressure, glucose and insulin metabolism, inflammatory context, body composition, visceral fat, smoking exposure, family history, and known plaque burden when available.

For a deeper discussion of atherogenic particle burden, see ApoB and Longevity: Why ApoB Matters More Than LDL for Heart Risk.

For more detail on Lp(a), see Lipoprotein(a) [Lp(a)]: The Genetic Risk Marker Most People Miss.

Lifestyle Still Matters Even When Lp(a) Is Genetic

Lp(a) differs from many cardiovascular biomarkers because its concentration is largely determined by genetics. Diet, exercise, weight loss, and supplements generally do not produce large or predictable reductions in the Lp(a) number itself.

The practical value of lifestyle lies elsewhere. Exercise improves blood pressure, insulin sensitivity, cardiorespiratory fitness, endothelial function, and body composition. A Mediterranean-style dietary pattern can improve the broader lipid and metabolic environment. Avoiding tobacco, maintaining healthy visceral fat, sleeping well, controlling blood pressure, and preventing or treating diabetes all reduce the cardiovascular burden surrounding an inherited risk factor.

The purpose of lifestyle intervention in a patient with high Lp(a) is therefore not to force the Lp(a) concentration lower. It is to reduce the probability that an inherited susceptibility becomes clinical cardiovascular disease.

What About Aspirin?

Lp(a) has both atherogenic and potentially prothrombotic properties, which has led to interest in whether aspirin might provide particular benefit in selected people with high Lp(a).

Some subgroup analyses from primary-prevention studies have suggested a greater cardiovascular benefit among people with genetically or clinically elevated Lp(a). The evidence remains insufficient to recommend aspirin routinely for everyone with a high Lp(a), particularly because aspirin also increases bleeding risk.

Age, plaque burden, cardiovascular risk, gastrointestinal history, bleeding history, and concurrent medications all affect the balance of benefit and harm. Aspirin therefore remains an individualized medical decision rather than a default response to an elevated Lp(a) result.

The Treatment Landscape for Lp(a) Is Changing

As of August 2026, there is still no FDA-approved medication whose primary indication is lowering Lp(a) for prevention of cardiovascular events in the general population with elevated Lp(a).

Several therapies designed specifically to reduce Lp(a) production are in advanced clinical development, including antisense oligonucleotides and small-interfering RNA approaches. Early and mid-stage studies have produced large reductions in circulating Lp(a), but lowering the laboratory value is only part of the question. The cardiovascular field is waiting for definitive evidence that targeted Lp(a) reduction lowers rates of myocardial infarction, stroke, and other major cardiovascular events.

PCSK9 inhibitors are available now for established lipid-lowering indications and can reduce Lp(a) by approximately 15% to 30% while substantially lowering LDL-C and apoB. They are not currently approved specifically as Lp(a)-lowering therapies. Niacin can also lower Lp(a), but contemporary cardiovascular guidelines do not recommend routine use for this purpose because biomarker reduction has not translated into sufficient proven clinical benefit to justify the adverse-effect burden.

When Should a Zero Calcium Score Be Repeated?

A CAC score of zero is a snapshot of coronary calcification at one point in time. It is not a permanent guarantee.

The 2026 ACC/AHA guideline suggests repeating CAC in approximately three to seven years in selected patients when an initial zero score was used to defer lipid-lowering therapy. The interval is individualized according to age and cardiovascular risk.

A person with very high Lp(a), a strong family history, worsening metabolic health, or accumulating risk factors may warrant a different follow-up strategy from someone whose initial calcium scan was performed only because of borderline calculated risk.

Repeat imaging is most useful when a change in the result would alter prevention rather than when scanning becomes an end in itself.

Symptoms Require a Different Approach

Coronary calcium scanning is primarily a risk-stratification tool in asymptomatic individuals. It should not be used to dismiss concerning cardiovascular symptoms.

A person can have CAC = 0 and still have noncalcified coronary plaque or another cardiovascular condition. Chest pressure, exertional discomfort, unexplained shortness of breath, syncope, new exercise intolerance, or other potentially concerning symptoms deserve appropriate diagnostic evaluation regardless of a previous calcium score.

The testing strategy for a symptomatic patient is therefore different from the strategy used for preventive screening in someone who feels well.

The HormoneSynergy® Approach

HormoneSynergy® approaches preventive cardiology by combining biomarkers, physiology, and imaging rather than asking any single test to define the entire cardiovascular picture.

Lp(a) provides information about inherited risk. ApoB helps quantify the overall burden of atherogenic particles. Blood pressure, glucose and insulin metabolism, body composition, smoking exposure, inflammation, exercise, sleep, and family history provide information about the modifiable environment in which atherosclerosis develops. CAC measures calcified coronary plaque, while CCTA can characterize calcified and noncalcified plaque when that additional information is clinically useful.

An elevated Lp(a) is not a reason for panic, and a zero calcium score is not a failed test because it does not confirm the concern created by the laboratory result. A favorable calcium score should be treated as favorable information. The inherited Lp(a) result should still influence the intensity and duration of prevention.

Our broader framework is described in the HormoneSynergy® Preventive Cardiology Protocol.

The Bottom Line

A coronary calcium score of zero and an elevated Lp(a) describe different parts of cardiovascular risk, and both deserve to be interpreted on their own terms.

CAC = 0 indicates that no calcified coronary plaque is detectable on the scan and is associated with a substantially lower short- and intermediate-term risk of cardiovascular events. Large cohort studies show that this favorable prognosis persists even among many people with elevated Lp(a).

High Lp(a) remains relevant because it represents inherited lifelong atherogenic exposure. Newer CCTA research also suggests that elevated Lp(a) may be associated with noncalcified and higher-risk plaque that a standard calcium scan cannot visualize.

The clinical response depends on the larger cardiovascular phenotype. Age, apoB, LDL-C, blood pressure, metabolic health, smoking, family history, symptoms, inflammatory disease, and known plaque burden all influence how aggressively prevention should proceed and whether additional imaging would be useful.

At HormoneSynergy®, we regard a zero calcium score as reassuring information while taking a high Lp(a) seriously as a long-term risk marker. The purpose is not to decide which test is “right,” but to use both results to build a more accurate picture of cardiovascular risk and prevention.

Frequently Asked Questions

Can you have high Lp(a) and a calcium score of zero?

Yes. Lp(a) reflects inherited cardiovascular risk, while a coronary calcium scan measures calcified coronary plaque that has already developed. A person can have genetically high Lp(a) without detectable coronary calcium.

Does CAC = 0 cancel the risk from high Lp(a)?

No, although it substantially lowers observed near-term risk. In MESA and the Dallas Heart Study, people with elevated Lp(a) and CAC = 0 had low cardiovascular event rates and did not have significantly greater observed risk than people with lower Lp(a) and CAC = 0. Elevated Lp(a) remains relevant to lifetime risk.

Does high Lp(a) mean I have coronary artery disease?

No. Elevated Lp(a) is a cardiovascular risk factor rather than a diagnosis of coronary artery disease. Imaging such as CAC or CCTA can assess whether coronary plaque is actually present.

Can a calcium score of zero miss plaque?

Yes. CAC scanning detects calcified plaque but does not directly visualize noncalcified plaque. Coronary CT angiography can identify both calcified and noncalcified coronary atherosclerosis.

Is high Lp(a) associated with noncalcified plaque?

Recent CCTA studies have associated elevated Lp(a) with greater noncalcified plaque burden and higher-risk plaque features. This does not mean every person with elevated Lp(a) has noncalcified plaque.

Do I need CCTA if my CAC is zero but Lp(a) is high?

Not automatically. CCTA may be useful when symptoms, family history, metabolic disease, elevated apoB, inflammatory conditions, or other cardiovascular risk factors create enough uncertainty that identifying noncalcified plaque would change management.

Should I take a statin if my CAC is zero and Lp(a) is high?

There is no universal answer. CAC = 0 can support deferring lipid-lowering treatment in selected lower-risk adults, while elevated Lp(a) favors more intensive management of modifiable cardiovascular risk. Age, apoB, LDL-C, diabetes, smoking, family history, blood pressure, estimated risk, and patient preference all influence the decision.

Do statins lower Lp(a)?

No. Statins do not meaningfully lower Lp(a) and may cause a small increase in some people. They can still substantially reduce LDL-C, apoB-containing particles, and cardiovascular event risk when appropriately prescribed.

Can diet and exercise lower Lp(a)?

Lifestyle generally has little effect on the Lp(a) concentration itself because the level is largely genetically determined. Healthy nutrition, exercise, smoking avoidance, blood-pressure control, weight management, and metabolic health remain important because they reduce the modifiable cardiovascular risks surrounding elevated Lp(a).

What level of Lp(a) is considered high?

The 2026 ACC/AHA dyslipidemia guideline considers Lp(a) of 125 nmol/L or 50 mg/dL and above elevated. Cardiovascular risk increases progressively as the concentration rises.

Are there medications specifically for high Lp(a)?

Several potent Lp(a)-lowering therapies are in advanced clinical trials, but as of August 2026 there is not yet an FDA-approved medication specifically indicated to lower Lp(a) for prevention of cardiovascular events in the general population with elevated Lp(a). PCSK9 inhibitors can reduce Lp(a) modestly while substantially lowering LDL-C and apoB.

How often should CAC be repeated after a score of zero?

The 2026 ACC/AHA guideline suggests repeat CAC testing in approximately three to seven years in selected adults when CAC = 0 was used to defer lipid-lowering therapy. Timing should be individualized according to age and cardiovascular risk.

Related HormoneSynergy® Reading

• Lp(a): The Inherited Heart Risk Most People Have Never Measured
• Lp(a) Thresholds: What Is High and What It Means for Cardiovascular Risk
• Calcium Score of Zero: Why It Doesn't Mean Zero Risk
• Coronary Artery Calcium Score Explained: Early Detection of Heart Disease
• Coronary Calcium Score vs CCTA with Cleerly® Plaque Analysis
• Cleerly® CCTA Heart Plaque Testing in Portland, Oregon
• HormoneSynergy® Preventive Cardiology Protocol

Selected Research and Clinical Guidance

• Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154-e1276. DOI: 10.1161/CIR.0000000000001423.
• Mehta A, Vasquez N, Ayers CR, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. Journal of the American College of Cardiology. 2022;79(8):757-768. PMID: 35210030. DOI: 10.1016/j.jacc.2021.11.058.
• The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention. European Journal of Preventive Cardiology. 2026. PMID: 42054506.
• Sebastian SA, et al. Association of Lp(a) with coronary plaque burden and high-risk plaque features: A meta-analysis of imaging studies. Atherosclerosis. 2026;415:120706. PMID: 41850136. DOI: 10.1016/j.atherosclerosis.2026.120706.
• Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation. 10-year serial CCTA study. PMID: 39018040.

Educational Notice: This article is for educational purposes and does not provide individualized medical advice. Cardiovascular testing and treatment decisions depend on age, symptoms, medical history, family history, blood pressure, lipid and metabolic markers, medications, kidney function, bleeding risk, and other individual factors. New chest discomfort, exertional symptoms, unexplained shortness of breath, fainting, or other potentially serious cardiovascular symptoms require appropriate medical evaluation.